Table 2.
Patient characteristics with isolated trisomy 12 (overall and per IGVH status).
| Trisomy 12 |
||||
|---|---|---|---|---|
| Overall (n=49) | IGHV<2% (n=32) | IGHV≥2% (n=17) | p Value* | |
| Age at diagnosis, median (range), years | 57 34–74 |
58 34–74 |
55 34–71 |
|
| Age | ||||
| Age >60 years | 31 (39.2%) | 17 (44.7%) | 14 (34.1% | .365 |
| Age <60 years | 48 (60.7%) | 21 (55.2%) | 27 (65.8%) | |
| Gender | ||||
| Male | 51 (64.5%) | 25 (65.7%) | 26 (63.4%) | 1 |
| Female | 28 (35.4%) | 13 (34.2%) | 15 (36.5%) | |
| Modified Rai staging | ||||
| Rai 0–II | 63 (78.4%) | 29 (76.3%) | 34 (82.9%) | .72 |
| Rai III–IV | 9 (10.1%) | 5 (13.1%) | 4 (9.7%) | |
| Unknown | 7 (11.4%) | 4 (10.5%) | 3 (7.3%) | |
| ZAP-70 | ||||
| >20% | 23 (27.8%) | 12 (31.5%) | 11 (26.8%) | .44 |
| <20% | 41 (41.7%) | 17 (44.7%) | 24 (58.5%) | |
| Unknown | 16 (30.3%) | 9 (23.6%) | 6 (14.6%) | |
| CD38 | ||||
| >30% | 20 (25.3%) | 18 (47.3%) | 12 (29.2%) | .08 |
| <30% | 37 (46.8%) | 14 (36.8%) | 23 (56.0%) | |
| Unknown | 12 (15.1%) | 6 (15.7%) | 6 (14.6%) | |
| β2M | ||||
| Elevated | 16 (20.2%) | 6 (15.7%) | 10 (24.3%) | .54 |
| Not elevated | 31 (39.2%) | 15 (39.4%) | 16 (39.0%) | |
| Unknown | 32 (40.5%) | 17 (44.7%) | 15 (36.5%) | |
| CLL treatment | ||||
| No | 40 (50.6%) | 14 (36.8%) | 26 (63.4%) | .02 |
| Yes | 39 (49.3%) | 24 (63.1%) | 15 (36.5%) | |
| Unknown | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
β2M: β2-microglobulin; CLL: chronic lymphocytic leukemia; IGVH: immunoglobulin variable heavy chain.
*
p<.05.